No abstract available
Plain language summary
This study evaluates whether FDA-approved novel cancer therapeutics supported by pivotal trials with adequate representation of minoritized groups were associated with slower clinical development times than those with inadequate representation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Clinical Trials as Topic*
-
Demography*
-
Diffusion of Innovation
-
Drug Approval*
-
Humans
-
Medical Oncology
-
Neoplasms* / therapy
-
Time Factors
-
United States
-
United States Food and Drug Administration